Department of Molecular and Experimental Medicine, The Scripps Research Institute, CA 92037, USA.
Biochemistry. 2011 May 24;50(20):4371-81. doi: 10.1021/bi200031m. Epub 2011 Apr 27.
Most protease-substrate assays rely on short, synthetic peptide substrates consisting of native or modified cleavage sequences. These assays are inadequate for interrogating the contribution of native substrate structure distal to a cleavage site that influences enzymatic cleavage or for inhibitor screening of native substrates. Recent evidence from HIV-1 isolates obtained from individuals resistant to protease inhibitors has demonstrated that mutations distal to or surrounding the protease cleavage sites in the Gag substrate contribute to inhibitor resistance. We have developed a protease-substrate cleavage assay, termed the cleavage enzyme- cytometric bead array (CE-CBA), which relies on native domains of the Gag substrate containing embedded cleavage sites. The Gag substrate is expressed as a fluorescent reporter fusion protein, and substrate cleavage can be followed through the loss of fluorescence utilizing flow cytometry. The CE-CBA allows precise determination of alterations in protease catalytic efficiency (k(cat)/K(M)) imparted by protease inhibitor resistance mutations in protease and/or gag in cleavage or noncleavage site locations in the Gag substrate. We show that the CE-CBA platform can identify HIV-1 protease present in cellular extractions and facilitates the identification of small molecule inhibitors of protease or its substrate Gag. Moreover, the CE-CBA can be readily adapted to any enzyme-substrate pair and can be utilized to rapidly provide assessment of catalytic efficiency as well as systematically screen for inhibitors of enzymatic processing of substrate.
大多数蛋白酶-底物测定依赖于由天然或修饰的切割序列组成的短合成肽底物。这些测定方法对于研究远离切割位点的天然底物结构对酶切割的影响或天然底物抑制剂筛选是不够的。最近从对蛋白酶抑制剂有抗性的个体中分离得到的 HIV-1 分离株的证据表明,Gag 底物中蛋白酶切割位点附近或周围的突变有助于抑制剂抗性。我们开发了一种蛋白酶-底物切割测定法,称为切割酶-流式细胞术微珠阵列(CE-CBA),它依赖于含有嵌入切割位点的 Gag 底物的天然结构域。Gag 底物被表达为荧光报告融合蛋白,并且可以通过流式细胞术检测荧光损失来跟踪底物切割。CE-CBA 可以精确确定蛋白酶抑制剂抗性突变对蛋白酶和/或 gag 在 Gag 底物的切割或非切割位点位置对蛋白酶催化效率(kcat/KM)的影响。我们表明,CE-CBA 平台可以鉴定细胞提取物中的 HIV-1 蛋白酶,并有助于鉴定蛋白酶或其底物 Gag 的小分子抑制剂。此外,CE-CBA 可以很容易地适应任何酶-底物对,并可用于快速评估催化效率,以及系统地筛选酶促处理底物的抑制剂。